UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Elevation Oncology Inc (ELEV)

Elevation Oncology Inc (ELEV)
0.3600 x 1 0.3780 x 78
Post-market by (Cboe BZX)
0.3720 -0.0061 (-1.61%) 04/22/25 [NASDAQ]
0.3600 x 1 0.3780 x 78
Post-market 0.3780 +0.0060 (+1.61%) 18:43 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.3600
Day High
0.3959
Open 0.3825
Previous Close 0.3781 0.3781
Volume 1,245,700 1,245,700
Avg Vol 1,522,395 1,522,395
Stochastic %K 92.45% 92.45%
Weighted Alpha -66.56 -66.56
5-Day Change +0.0782 (+26.62%) +0.0782 (+26.62%)
52-Week Range 0.2210 - 4.4900 0.2210 - 4.4900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,393
  • Shares Outstanding, K 59,224
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,490 K
  • EBIT $ -45 M
  • EBITDA $ -46 M
  • 60-Month Beta 1.65
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.38
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.81
  • Most Recent Earnings $-0.18 on 03/06/25
  • Next Earnings Date 05/01/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 496.75% ( -297.47%)
  • Historical Volatility 178.50%
  • IV Percentile 60%
  • IV Rank 61.06%
  • IV High 803.46% on 02/10/25
  • IV Low 15.89% on 06/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 1,441
  • Open Int (30-Day) 2,416

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 5
  • High Estimate -0.18
  • Low Estimate -0.21
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2210 +68.33%
on 04/09/25
Period Open: 0.3001
0.3959 -6.04%
on 04/22/25
+0.0719 (+23.96%)
since 03/21/25
3-Month
0.2210 +68.33%
on 04/09/25
Period Open: 0.6700
0.7924 -53.05%
on 01/23/25
-0.2980 (-44.48%)
since 01/22/25
52-Week
0.2210 +68.33%
on 04/09/25
Period Open: 4.0500
4.4900 -91.71%
on 04/23/24
-3.6780 (-90.81%)
since 04/22/24

Most Recent Stories

More News
Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic...

CTMX : 0.7361 (-1.84%)
ETNB : 6.55 (+4.47%)
ELEV : 0.3720 (-1.61%)
ANIP : 68.95 (+1.40%)
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

/CNW/ -- As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in...

ONCY : 0.6000 (+4.35%)
ELEV : 0.3720 (-1.61%)
ORIC : 5.22 (+7.19%)
ADPT : 7.01 (+2.64%)
NEO : 9.75 (+1.77%)
ONC.TO : 0.84 (+6.33%)
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted...

CSTL : 21.98 (+3.97%)
ELEV : 0.3720 (-1.61%)
FATE : 1.3700 (+9.60%)
ALKS : 27.11 (+0.41%)
5 Biotech Stocks Under $10 With Multibagger Potential

As the biotech industry continues to redefine the healthcare landscape, here are five penny biotech stocks poised for meteoric growth in this evolving industry.

$SPX : 5,287.76 (+2.51%)
RZLT : 3.11 (-0.96%)
TRVI : 6.07 (+0.83%)
ELEV : 0.3720 (-1.61%)
CRDL : 0.9900 (+2.06%)
ADCT : 1.2300 (unch)
Up 825% So Far in 2024, Can This Penny Stock Go Any Higher?

Despite its outsized year-to-date gains, Wall Street expects this breakout penny stock to soar 55% higher, on average.

$SPX : 5,287.76 (+2.51%)
ELEV : 0.3720 (-1.61%)
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 0.6000 (+4.35%)
NKTX : 2.2200 (+20.00%)
AMAM : 28.00 (+0.07%)
ELEV : 0.3720 (-1.61%)
ONC.TO : 0.84 (+6.33%)
AMGN : 278.40 (+1.72%)
Elevation Oncology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.3720 (-1.61%)
Elevation Oncology Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating EO-3021

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.3720 (-1.61%)
Elevation Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Business Achievements

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.3720 (-1.61%)
Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

ELEV : 0.3720 (-1.61%)

Business Summary

Elevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 0.4278
2nd Resistance Point 0.4119
1st Resistance Point 0.3919
Last Price 0.3720
1st Support Level 0.3560
2nd Support Level 0.3401
3rd Support Level 0.3201

See More

52-Week High 4.4900
Fibonacci 61.8% 2.8592
Fibonacci 50% 2.3555
Fibonacci 38.2% 1.8518
Last Price 0.3720
52-Week Low 0.2210

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro